Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients

Abstract

ABSTRACT. The present study aimed to explore the changes in serum endostatin and fibroblast growth factor 19 (FGF-19) in acute myeloid leukemia patients, and to determine their effects on chemotherapeutic sensitivity. Sixty acute myeloid leukemia patients and 30 healthy controls were included in the study. Patient serum endostatin and FGF-19 levels were measured on admission, and then, standard chemotherapy was administered. The patients were divided into 2 groups according to chemotherapeutic effects: 21 patients in the chemotherapeutic sensitivity group (complete remission + partial remission) and 39 in the chemotherapeutic resistance group (no remission + degradation). A receiver operating characteristic (ROC) curve was used to analyze the relationship of serum endostatin and FGF-19 levels with chemotherapeutic sensitivity in acute myeloid leukemia patients. The levels of serum endostatin and FGF-19 in acute myeloid leukemia patients before chemotherapy were significantly higher than those in the control group. Moreover, these levels significantly decreased after chemotherapy (P < 0.01). The levels of serum endostatin and FGF-19 in the chemotherapeutic sensitivity group were lower than those in the chemotherapeutic resistance group, both before and after chemotherapy (P < 0.05 and P < 0.01, respectively). ROC curve analysis showed that the predictive values of endostatin and FGF-19 were good, and there was no significant difference between these results. In conclusion, serum endostatin and FGF-19 can be used as predictors of chemotherapeutic sensitivity for acute myeloid leukemia patients, and may be important for determining prognosis.

Global expression profiling of CD10 + /CD19 + pre-B lymphoblasts from Hispanic B-ALL patients correlates with comparative TARGET database analysis

“…FGFR are required for the biological activities of FGF; the activated FGFR phosphorylate specific tyrosine residues that mediate interaction with the JAK/STAT, PI3K-AKT, and RAS-MAPK pathways [44]. Su et al [45] observed that the levels of FGF-19 in AML patients before chemotherapy were significantly higher than those in a control group. Although FGF19 was not among the DEGs of our global expression analysis, thus was not validated by RT-qPCR, our ARACNE results revealed that it was involved in pre-B ALL.…”

Analysis of Cellular and Biochemical Factors Involved in Acute Myeloid Leukemia Taking Into Account the Dysfunctional Module

“…It has been confirmed that the sensitivity of serum endostatin and fibroblast growth factor 19 (FGF-19) is predicted by ROC curve analysis, thus affecting the occurrence of acute myeloid leukemia [12]. Studies have shown that the treatment of acute lymphoblastic leukemia (ALL) by bispecific T cell antigen-antibody isocitrate dehydrogenase (IDH) has made significant achievements in clinical practice [13].…”

FIBP is a prognostic biomarker and correlated with clinicalpathological characteristics and immune infiltrates in acute myeloid leukemia

“…It is associated with genomic alterations in cell proliferation and differentiation [ 1 , 2 ]. It has a high incidence accounts for approximately 60% of all leukemia [ 3 ]. It seriously endangers human health and life.…”

“…It seriously endangers human health and life. Chemotherapies are the main treatment for acute myeloid leukemia [ 3 , 4 ]. However, there are still poor prognosis and short disease-free survival after chemotherapy.…”